After her second round of chemo, with her ovarian cancer in remission, Marie started taking a mixed-media art class. Around this same time, Marie began taking maintenance treatment as part of the NOVA study. As the weeks turned to months without cancer recurring Marie’s art became her passion. Maintenance treatment with ZEJULA has given Marie time to create and exhibit her work at galleries. Her proudest composition is shared with you here.

Give a woman the time to discover she's an artist
Give a woman the time to discover she's an artist.

ZEJULA is the first and only once-daily PARP inhibitor for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy.1-3

See the Pivotal Trial Data

More Time for More Women1

ZEJULA increased progression-free survival (PFS) for women with recurrent ovarian cancer following complete or partial response to platinum-based chemotherapy in a randomized, placebo-controlled phase 3 trial.1,4

Median PFS in the Pivotal Trial

  • At the time of the PFS analysis, limited overall survival data were available, with 17% of survival events occurring in the study (HR=0.73; 95% CI, 0.48-1.13; P=0.15).1,5

BRCA, breast cancer susceptibility gene; CI, confidence interval; gBRCAmut, germline BRCA mutated; HR, hazard ratio; non-gBRCAmut, not germline BRCA mutated; NS, not significant; PARP, poly(ADP-ribose) polymerase; PFS, progression-free survival.

Efficacy summary

EFFICACY SUMMARY

See the clinical efficacy summary for ZEJULA

See Summary

Safety data

SAFETY DATA

Learn about the safety and tolerability of ZEJULA

See Safety

Dosing

DOSING

See recommendations for dose adjustment of ZEJULA

Review Dosing

TOGETHER with TESARO®

ACCESS

TESARO offers a suite of access and affordability solutions

About Access

Get the latest news about ZEJULA

Sign up below
*Required field

By clicking submit, you agree to TESARO’s Terms of Use and Privacy Policy and to receive product and disease-state information from TESARO, its affiliates, service providers, and co-promotion partners.